Stolper Co cut its holdings in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 11.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,502 shares of the company's stock after selling 5,238 shares during the period. DaVita makes up approximately 1.4% of Stolper Co's investment portfolio, making the stock its 27th largest holding. Stolper Co's holdings in DaVita were worth $3,099,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ellevest Inc. lifted its holdings in DaVita by 1,388.0% during the third quarter. Ellevest Inc. now owns 372 shares of the company's stock worth $31,000 after acquiring an additional 347 shares in the last quarter. Eisler Capital UK Ltd. bought a new position in DaVita during the third quarter worth about $35,000. Parkside Financial Bank & Trust lifted its holdings in DaVita by 88.6% during the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company's stock worth $35,000 after acquiring an additional 147 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in shares of DaVita in the 3rd quarter valued at about $40,000. Finally, Wipfli Financial Advisors LLC acquired a new stake in shares of DaVita in the 3rd quarter valued at about $44,000. 86.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Sanford C. Bernstein assumed coverage on DaVita in a research note on Tuesday, March 7th. They issued a "market perform" rating on the stock. Cowen lifted their price target on DaVita from $76.00 to $90.00 and gave the company an "outperform" rating in a research note on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on DaVita from $72.00 to $85.00 in a research note on Thursday, February 23rd. Truist Financial lifted their price target on DaVita from $84.00 to $90.00 and gave the company a "hold" rating in a research note on Thursday, February 23rd. Finally, StockNews.com began coverage on DaVita in a research note on Thursday. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $86.43.

DaVita Stock Down 1.6 %

Shares of NYSE:DVA traded down $1.26 during midday trading on Friday, reaching $76.77. The company had a trading volume of 1,076,574 shares, compared to its average volume of 694,003. The company has a quick ratio of 1.16, a current ratio of 1.20 and a debt-to-equity ratio of 9.92. The business's 50 day moving average price is $80.92 and its 200 day moving average price is $80.60. The stock has a market cap of $6.94 billion, a PE ratio of 13.28, a P/E/G ratio of 1.53 and a beta of 0.95. DaVita Inc. has a 1-year low of $65.28 and a 1-year high of $124.81.

DaVita (NYSE:DVA – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.23. The firm had revenue of $2.92 billion for the quarter, compared to the consensus estimate of $2.93 billion. DaVita had a return on equity of 74.02% and a net margin of 4.83%. The business's revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 earnings per share. Research analysts forecast that DaVita Inc. will post 5.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, Director Charles Berg sold 735 shares of the business's stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $81.78, for a total transaction of $60,108.30. Following the transaction, the director now owns 17,164 shares of the company's stock, valued at $1,403,671.92. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.00% of the company's stock.

About DaVita

(Get Rating)

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Featured Stories

• Get a free copy of the StockNews.com research report on DaVita (DVA)
• MarketBeat Week in Review – 3/13 – 3/17
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Get Rating).

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.